Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 421 to 424 of 424 results for cost benefit of cancer drugs

  1. NICE has recommended a new option for people with difficult-to-treat multiple myeloma

    Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma.

    News
    Last updated
    19 January 2024

  2. NICE recommends 'game changing' histology independent cancer drug

    Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).

    News
    Last updated
    15 January 2024

  3. NICE recommends new chemotherapy-free treatment option for people with untreated chronic lymphocytic leukaemia

    More than 1,000 people each year will benefit from NICE's recommendation.

    News
    Last updated
    15 January 2024

  4. Additional evidence needed to assess histology-independent cancer drugs

    A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.

    News
    Last updated
    20 December 2023